Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC order

This article was originally published in The Tan Sheet

Executive Summary

The Federal Trade Commission files a stipulated final order against Stephen Karian and supplement marketers Great American Products and Physician's Choice for violating a court order in advertising for products. The original court order filed in 2005 specifically required the defendants clearly, prominently and frequently place paid advertising disclosures before product-ordering instructions during their infomercials for supplement products. The latest court order, filed Jan. 29, states the defendants must display a visual disclosure of paid advertising continuously throughout ordering instructions during TV ads and also requires audio paid advertising disclosures during radio and TV ads. The firms were ordered to pay the largest-ever FTC health fraud settlement in 2005 for deceptively claiming products increased human growth hormone levels (1"The Tan Sheet" June. 13, 2005, p. 18)...

You may also be interested in...

“Hormone Booster” Firms To Pay Largest Ever FTC Health Fraud Settlement

Marketers of products deceptively claiming to increase human growth hormone (HGH) levels are required to pay up to $20 mil. in consumer redress under a settlement, the Federal Trade Commission announced June 9

Prenatal Vitamin D Benefit In Preventing Childhood Asthma Fades By Age 6

University of Rochester researchers say a benefit of daily prenatal vitamin D in preventing asthma in children up to 3 found in their 2016 study doesn't extend until age 6. They encourage more research, including analyzing whether supplementation should continue in young children.

UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System

At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts